Security
Axsome Therapeutics, Inc. Common Stock · AXSM
AXSMNASDAQCommon stockCurrentCIK 1579428Updated Nov 3, 2026
AXSM price & chart
Loading TradingView…
NASDAQ:AXSM on TradingView ↗About the company
Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, agitation associated with dementia due to Alzheimer’s disease, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, as well as multiple novel product candidates addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at www.axsome.com and follow us on LinkedIn and X.
In the news
Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026 ↗
Seeking Alpha
Axsome Therapeutics: Sentiment Meets Reality After Q3 (Rating Upgrade) ↗
Axsome projects AUVELITY peak revenue of at least $8B as AXS-12 nears May 1, 2027 PDUFA ↗
Axsome Therapeutics, Inc. (AXSM) Q3 2026 Earnings Call Transcript ↗
SEC disclosures
Axsome Therapeutics, Inc. files 8-K: Material Event ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition · Other Events
Items 2.02, 8.01, 9.01
10-Q filing
Results of Operations and Financial Condition · Other Events
Items 2.02, 8.01, 9.01
4 filing
Show 5 more recent filings
Other Events
Items 8.01, 9.01
4 filing
4 filing
4 filing
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 669,250,000Source | 561,458,000Source | 761,447,000Source | 639,785,000Source | 548,226,000Source | 713,607,000Source | 596,671,000Source | 545,728,000Source | 689,805,000Source | 568,498,000Source | 588,236,000Source | 331,476,095Source |
| Property, Plant and Equipment, NetUSD | 605,000Source | 683,000Source | 874,000Source | 667,000Source | 724,000Source | 567,000Source | 773,000Source | 812,000Source | 562,000Source | 584,000Source | 846,000Source | 722,515Source |
| GoodwillUSD | 12,042,000Source | 12,042,000Source | 12,042,000Source | 12,042,000Source | 12,042,000Source | 12,042,000Source | 12,042,000Source | 12,042,000Source | 12,042,000Source | 12,042,000Source | 12,042,000Source | 10,310,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 42,126,000Source | 48,501,000Source | 37,358,000Source | 43,733,000Source | 50,107,000Source | 38,947,000Source | 45,322,000Source | 51,697,000Source | 40,519,000Source | 46,894,000Source | 53,286,000Source | 59,660,772Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 325,272,000Source | 327,341,000Source | 319,850,000Source | 303,016,000Source | 315,657,000Source | 305,106,000Source | 300,910,000Source | 331,441,000Source | 322,933,000Source | 315,353,000Source | 386,193,000Source | 200,841,955Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 196,507,000Source | 124,096,000Source | 277,459,000Source | 198,825,000Source | 120,342,000Source | 251,062,000Source | 161,398,000Source | 101,434,000Source | 224,464,000Source | 142,001,000Source | 94,820,000Source | 37,698,868Source |
| Inventory, NetUSD | 23,774,000Source | 14,265,000Source | 37,883,000Source | 18,441,000Source | 15,220,000Source | 31,515,000Source | 16,319,000Source | 15,583,000Source | 27,938,000Source | 15,732,000Source | 15,135,000Source | 4,319,921Source |
| Assets, CurrentUSD | 565,342,000Source | 479,113,000Source | 656,569,000Source | 536,620,000Source | 463,027,000Source | 611,206,000Source | 494,634,000Source | 460,490,000Source | 588,986,000Source | 485,064,000Source | 504,263,000Source | 245,641,409Source |
| Prepaid Expense and Other Assets, CurrentUSD | 19,789,000Source | 13,411,000Source | 21,377,000Source | 16,338,000Source | 11,808,000Source | 23,523,000Source | 16,007,000Source | 12,032,000Source | 13,651,000Source | 11,978,000Source | 8,115,000Source | 2,780,665Source |
| Operating Lease, Right-of-Use AssetUSD | 21,654,000Source | 5,730,000Source | 19,157,000Source | 22,472,000Source | 6,071,000Source | 20,014,000Source | 23,294,000Source | 6,411,000Source | 20,858,000Source | 5,383,000Source | 6,772,000Source | 420,298Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 595,523,000Source | 468,560,000Source | 678,143,000Source | 566,710,000Source | 445,374,000Source | 659,020,000Source | 543,466,000Source | 401,692,000Source | 601,510,000Source | 511,483,000Source | 397,259,000Source | 221,919,686Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 5,000Source | 5,000Source | 5,000Source | 5,000Source | 5,000Source | 5,000Source | 5,000Source | 5,000Source | 5,000Source | 5,000Source | 5,000Source | 4,350Source |
| Retained Earnings (Accumulated Deficit)USD | -1,277,402,000Source | -1,047,875,000Source | -1,421,817,000Source | -1,230,173,000Source | -983,273,000Source | -1,370,503,000Source | -1,182,200,000Source | -903,928,000Source | -1,305,961,000Source | -1,122,787,000Source | -835,571,000Source | -596,332,736Source |
| Stockholders' Equity Attributable to ParentUSD | 73,727,000Source | 92,898,000Source | 83,304,000Source | 73,075,000Source | 102,852,000Source | 54,587,000Source | 53,205,000Source | 144,036,000Source | 88,295,000Source | 57,015,000Source | 190,977,000Source | 109,556,409Source |
| Additional Paid in Capital, Common StockUSD | 1,351,124,000Source | 1,140,768,000Source | 1,505,116,000Source | 1,303,243,000Source | 1,086,120,000Source | 1,425,085,000Source | 1,235,400,000Source | 1,047,959,000Source | 1,394,251,000Source | 1,179,797,000Source | 1,026,543,000Source | 705,884,795Source |
| Liabilities and EquityUSD | 669,250,000Source | 561,458,000Source | 761,447,000Source | 639,785,000Source | 548,226,000Source | 713,607,000Source | 596,671,000Source | 545,728,000Source | 689,805,000Source | 568,498,000Source | 588,236,000Source | 331,476,095Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 360,290,000Source | 196,187,000Source | 460,446,000Source | 342,099,000Source | 186,570,000Source | 439,211,000Source | 243,914,000Source | 144,048,000Source | 378,836,000Source | 230,104,000Source | 138,854,000Source | 96,560,798Source |
| Operating Lease, Liability, CurrentUSD | 736,000Source | 1,627,000Source | 646,000Source | 337,000Source | 1,419,000Source | 628,000Source | 454,000Source | 1,153,000Source | 434,000Source | 1,835,000Source | 1,267,000Source | 424,673Source |
| Accounts Payable, CurrentUSD | 54,227,000Source | 64,253,000Source | 78,969,000Source | 91,628,000Source | 61,340,000Source | 106,702,000Source | 85,659,000Source | 53,791,000Source | 65,537,000Source | 71,997,000Source | 40,679,000Source | 38,605,312Source |
| Operating Lease, Liability, NoncurrentUSD | 23,041,000Source | 6,440,000Source | 21,574,000Source | 23,624,000Source | 6,829,000Source | 22,385,000Source | 23,905,000Source | 7,258,000Source | 23,182,000Source | 6,046,000Source | 7,035,000Source | — |
| Additional Financial Items | ||||||||||||
| Long-term Debt, Current MaturitiesUSD | 70,000,000Source | — | 70,000,000Source | 70,000,000Source | — | 70,000,000Source | — | — | 70,000,000Source | — | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 117,642,000Source | 180,002,000Source | 117,958,000Source | 117,540,000Source | 179,330,000Source | 117,850,000Source | 181,377,000Source | 178,689,000Source | 117,746,000Source | 180,710,000Source | 178,070,000Source | 94,258,888Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -47,229,000Source | -64,602,000Source | -51,314,000Source | -47,973,000Source | -64,542,000Source | -59,413,000Source | -183,174,000Source | -287,216,000Source | -239,238,000Source | -187,133,651Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 23,103,000Source | 21,660,000Source | 27,148,000Source | 24,611,000Source | 23,438,000Source | 23,308,000Source | 93,752,000Source | 85,218,000Source | 62,620,000Source | 37,726,158Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 26,598,000Source | 19,396,000Source | 82,463,000Source | 47,181,000Source | 57,121,000Source | 37,698,868Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 3,110,000Source | 249,000Source | 10,660,000Source | -744,000Source | 8,156,000Source | 1,330,916Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 41,165,000Source | 13,662,000Source | -6,460,000Source | 31,318,000Source | 2,074,000Source | 25,455,983Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -20,700,000Source | -43,375,000Source | -93,405,000Source | -128,410,000Source | -145,080,000Source | -116,510,798Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -121,000Source | -338,000Source | -480,000Source | -270,000Source | -582,000Source | -53,702,109Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 121,000Source | 338,000Source | 480,000Source | 270,000Source | 582,000Source | 702,109Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 9,301,000Source | 4,336,000Source | 7,110,000Source | 3,952,000Source | 1,835,000Source | 531,831Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 2,994,000Source | 29,270,000Source | 101,465,000Source | 57,840,000Source | 331,013,000Source | 284,582,008Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | 70,000,000Source | — | 331,988,000Source | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -17,827,000Source | -14,443,000Source | 7,580,000Source | -70,840,000Source | 185,351,000Source | 114,369,101Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 325,272,000Source | 327,341,000Source | 319,850,000Source | 303,016,000Source | 305,106,000Source | 300,910,000Source | 322,933,000Source | 315,353,000Source | 386,193,000Source | 200,841,955Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 2,932,000Source | 4,590,000Source | 14,626,000Source | 19,690,000Source | 16,730,000Source | 7,686,292Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | -180,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 23,103,000Source | 21,660,000Source | 27,148,000Source | 24,611,000Source | 23,438,000Source | 23,308,000Source | 93,752,000Source | 85,218,000Source | 62,620Source | 37,726,158Source |
| Amortization of Debt Issuance CostsUSD | — | — | — | 375,000Source | — | 134,000Source | — | 393,000Source | 527,000Source | 1,475,000Source | 1,197,000Source | 668,051Source |
| Amortization of Intangible AssetsUSD | — | — | 1,607,000Source | 1,606,000Source | 1,589,000Source | 1,589,000Source | 1,572,000Source | 1,572,000Source | 6,375,000Source | 6,392,000Source | 6,375,000Source | 4,139,228Source |
| DepreciationUSD | — | — | — | — | — | — | 116,000Source | 149,000Source | 503,000Source | 532,000Source | 459,000Source | 263,440Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | 0Source | -10,385,000Source | — | — | -10,385,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 19,739,000Source | 11,587,000Source | 24,615,000Source | 13,234,000Source | 22,024,000Source | 11,650,000Source | 63,273,000Source | 54,204,000Source | — | — |
| GoodwillUSD | — | — | 12,042,000Source | 12,042,000Source | 12,042,000Source | 12,042,000Source | 12,042,000Source | 12,042,000Source | 12,042,000Source | 12,042,000Source | 12,042,000Source | 10,310,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 128,000Source | -960,000Source | 0Source | 0Source | -530,000Source | 85,000Source | 960,000Source | 0Source |
| Inventory Write-downUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -47,229,000Source | -64,602,000Source | -51,314,000Source | -47,973,000Source | -64,542,000Source | -59,413,000Source | -183,174,000Source | -287,216,000Source | -239,238,000Source | -187,133,651Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 2,200,000Source | 1,255,165Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 6,343,000Source | 19,650,000Source | 67,904,000Source | 40,784,000Source | 258,750,000Source | 236,788,056Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | 17,035,000Source | — | — | 12,419,000Source | 6,251,173Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 170,992,000Source | 104,762,000Source | 218,375,000Source | 150,042,000Source | 191,203,000Source | 121,463,000Source | 638,496,000Source | 385,693,000Source | 270,600,000Source | 50,037,106Source |
| Cost of Goods and Services Sold | — | — | — | — | — | — | — | — | — | — | — | —Source |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | 150,235,000Source | 95,564,000Source | 208,137,000Source | 130,280,000Source | 184,996,000Source | 120,787,000Source | 570,599,000Source | 411,359,000Source | 323,123,000Source | 159,253,661Source |
| Operating Income (Loss)USD | — | — | -46,109,000Source | -62,624,000Source | -49,646,000Source | -36,714,000Source | -63,357,000Source | -56,982,000Source | -166,762,000Source | -280,562,000Source | -231,825,000Source | -179,799,055Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -47,229,000Source | -64,602,000Source | -51,186,000Source | -48,933,000Source | -64,542,000Source | -59,413,000Source | -183,704,000Source | -287,131,000Source | -238,278,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 128,000Source | -960,000Source | 0Source | 0Source | -530,000Source | 85,000Source | 960,000Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -47,229,000Source | -64,602,000Source | -51,314,000Source | -47,973,000Source | -64,542,000Source | -59,413,000Source | -183,174,000Source | -287,216,000Source | -239,238,000Source | -187,133,651Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.94Source | -1.34Source | -0.99Source | -0.97Source | -1.26Source | -1.22Source | -3.68Source | -5.99Source | -5.27Source | -4.6Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.94Source | -1.34Source | -0.99Source | -0.97Source | -1.26Source | -1.22Source | -3.68Source | -5.99Source | -5.27Source | -4.6Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 50,021,851Source | 48,140,519Source | 51,799,708Source | 49,442,001Source | 51,198,349Source | 48,871,163Source | 49,747,178Source | 47,914,253Source | 45,425,212Source | 40,655,941Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 50,021,851Source | 48,140,519Source | 51,799,708Source | 49,442,001Source | 51,198,349Source | 48,871,163Source | 49,747,178Source | 47,914,253Source | 45,425,212Source | 40,655,941Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 1,607,000Source | 1,606,000Source | 1,589,000Source | 1,589,000Source | 1,572,000Source | 1,572,000Source | 6,375,000Source | 6,392,000Source | 6,375,000Source | 4,139,228Source |
| Cost of Goods and Service, Excluding Depreciation, Depletion, and AmortizationUSD | — | — | 11,912,000Source | 8,437,000Source | 13,564,000Source | 13,448,000Source | 14,725,000Source | 9,789,000Source | 47,478,000Source | 33,303,000Source | 26,065,000Source | 5,197,595Source |
| Costs and ExpensesUSD | — | — | 217,101,000Source | 167,386,000Source | 268,021,000Source | 186,756,000Source | 254,560,000Source | 178,445,000Source | 805,258,000Source | 666,255,000Source | 502,425,000Source | 229,836,161Source |
| General and Administrative ExpenseUSD | — | — | 19,739,000Source | 11,587,000Source | 24,615,000Source | 13,234,000Source | 22,024,000Source | 11,650,000Source | 63,273,000Source | 54,204,000Source | — | — |
| Interest ExpenseUSD | — | — | -3,375,000Source | -5,666,000Source | -3,200,000Source | -4,086,000Source | 3,092,000Source | 5,258,000Source | -15,928,000Source | -21,581,000Source | — | — |
| Interest Income, OperatingUSD | — | — | 2,255,000Source | 3,688,000Source | 1,660,000Source | 2,252,000Source | 1,907,000Source | 2,827,000Source | 9,371,000Source | 15,012,000Source | — | — |
| Investment Income, NetUSD | — | — | -1,120,000Source | -1,978,000Source | -1,540,000Source | -1,834,000Source | -1,185,000Source | -2,431,000Source | -6,557,000Source | -6,569,000Source | -6,453,000Source | -7,334,596Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 2,200,000Source | 1,255,165Source |
| Research and Development ExpenseUSD | — | — | 40,162,000Source | 45,388,000Source | 46,227,000Source | 49,541,000Source | 52,677,000Source | 44,785,000Source | 183,279,000Source | 187,077,000Source | 97,944,000Source | 57,947,447Source |
| Selling and Marketing ExpenseUSD | — | — | 114,200,000Source | 68,186,000Source | 164,113,000Source | 99,376,000Source | 146,437,000Source | 92,288,000Source | 440,402,000Source | 293,355,000Source | — | — |
Filing attachments
axsm-ex99_1.htm · 8-K · 2026-11-02
Exhibit 99.1 Axsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update Total 3Q 2026 net product revenue of $259.7 million, representing 52% year-over-year growth AUVELITY® 3Q 2026 net product sales of $207.6 million, representing 53% year-over-year growth SUNOSI® 3Q 2026 net product revenue of $48.2 million, representing 47% year-over-year growth SYMBRAVO® 3Q 2026 net product sales of $3.9 million, representing 88% year-over-year growth SUMMIT Phase 3 t…
Read attachment ↗axsm-ex99_2.htm · 8-K · 2026-11-02
Advancing the frontiers of brain health Certain matters discussed in this presentation are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and pot…
Read attachment ↗axsm-ex99_1.htm · 8-K · 2026-08-10
EX-99.1 2 axsm-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Total 2Q 2026 net product revenue of $218.4 million, representing 46% year-over-year growth AUVELITY® 2Q 2026 net product sales of $180.3 million, representing 51% year-over-year growth SUNOSI® 2Q 2026 net product revenue of $35.8 million, representing 20% year-over-year growth SYMBRAVO® 2Q 2026 net product sales of $2.3 million AUVELITY…
Read attachment ↗axsm-ex99_2.htm · 8-K · 2026-08-10
EX-99.2 3 axsm-ex99_2.htm EX-99.2 August 10, 2026 2Q 2026 Financial Results Forward looking statements & safe harbor Certain matters discussed in this presentation are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-loo…
Read attachment ↗axsm-ex99_1.htm · 8-K · 2026-07-15
EX-99.1 2 axsm-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy FDA sets PDUFA target action date of May 1, 2027 NEW YORK, July 15, 2026 (Globe Newswire) - Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has acc…
Read attachment ↗axsm-ex99_1.htm · 8-K · 2026-06-03
EX-99.1 2 axsm-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation NEW YORK, June 3, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has resolved all patent litigation related to Axsome’s product SUNOSI (solriamfetol). The litigations resulted from su…
Read attachment ↗